# Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

> **NCT03146468** · PHASE2 · UNKNOWN · sponsor: **Melbourne Health** · enrollment: 14 (estimated)

## Conditions studied

- Haematological Malignancy

## Interventions

- **DRUG:** Nivolumab Injection

## Key facts

- **NCT ID:** NCT03146468
- **Lead sponsor:** Melbourne Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-08
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03146468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03146468, "Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03146468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*